RELATIONSHIP BETWEEN MENTAL ILLNESS AND MENTAL WELLBEING
Dr Matthew Iasiello, Head of Data and Research Translation, Be Well Co,
SAHMRI (South Australian Health and Medical Research Institute) &
Post Doctoral Researcher, University of Adelaide
RESEARCHER PROFILE
Filmed in Adelaide, South Australian | December 2024
Since 2015, Dr Matthew Iasiello has been working on the development and dissemination of mental wellbeing interventions across the Australian community at the South Australian Health and Medical Research Institute (SAHMRI). His PhD research was designed specifically to strengthen the translational work conducted by SAHMRI, and to solve problems that represented gaps in the literature that were arising when delivering mental wellbeing interventions into the community. The impact and relevance of Dr Iasiello’s work has been demonstrated with invited presentations at international academic conferences, and multiple media stories with significant online engagements.
Dr Iasiello’s research investigates the dual-continua model, an innovative model of mental health. The dual-continua model of mental health suggests that mental illness and mental wellbeing reflect distinct continua, rather than the extreme ends of a single spectrum. This novel conceptualisation of the relationship between mental illness and mental wellbeing has significant implications in the way we promote mental health, and prevent, treat, and recover from mental illness. However, little is known about the evidence validating the model, and whether this evidence supports the implications that have been proposed in the literature.
Dr Iasiello’s PhD project synthesises the relevant evidence supporting the model, provides further evidence of the role of mental wellbeing in the recovery of mental illness, and addresses important limitations in the current assessment of mental wellbeing in the context of psychological distress and mental illness.
He is engaged in the development of mental wellbeing services and products that emerge directly from the new knowledge generated from his PhD, translated into the community via SAHMRI. This has resulted in the development and evaluation of the Be Well Plan (https://www.bewellco.io/bwt), and evidence-based wellbeing intervention (over 5,000 participants since 2020), and the Be Well Tracker https://www.bewellco.io/be-well-plan, a free online assessment platform that Australians can use to assess and monitor their mental health (20,000 users since 2019).
-
Mental wellbeing in rural and regional communities dealing with environmental challenges
Associate Professor Suzie Cosh is a psychologist and clinical researcher. Her work focuses on the intersection of climate change and mental health and she currently leads a body of work that focuses on supporting small rural communities to recover from and prepare for extreme weather events such as bushfires, floods and droughts.
-
Life-changing donor milk for preterm babies
Dr Laura Klein is National Milk Research Leader at Australian Red Cross Lifeblood. Australian Red Cross Lifeblood is funded by Australian governments to provide life-giving blood, plasma, and transplantation and biological products.
Dr Klein works with clinicians and researchers across Australia to understand how donated breast milk can be used to improve outcomes for vulnerable babies. She’s passionate about generating evidence to improve the products and services that milk banks provide to donors and the families who receive donated breast milk.
-
Oral administration of insulin for Type 1 Diabetes
Huiwen Pang is a 3rd year PhD candidate in the Australian Institute for Bioengineering and Nanotechnology, University of Queensland, focusing on biomedical health research. Prior to commencing his PhD, Huiwen studied animal genetics in his Masters degree at Huazhong Agriculture University in China.
People with diabetes, especially Type 1 diabetes, largely rely on the insulin injections or insulin pumps to control their high blood glucose levels, which is painful and has a high risk of infections.
Huiwen Pang is conducting research on nano-based drug formulations for Type 1 diabetes treatment, with a focus on using nanomaterials to load insulin for oral administration and employing anti-apoptotic and anti-inflammatory approaches to mitigate damage to beta cells.
